研究文章
重组人促甲状腺激素和甲状腺激素撤退放射性碘治疗分化型甲状腺癌的淋巴结转移性疾病
表1
(一)基线特征。(b)甲状腺癌分期和初始RAI治疗。
| (一) |
|
| 参数 |
失业的
() |
rhTSH
() |
价值 |
|
| 年龄消融 |
|
|
|
| 平均数±标准差(年) |
38.2±12.4 |
45.7±16.2 |
0.039 |
| < 45岁 |
23 (74%) |
22 (52%) |
0.075 |
| > 45 |
8 (26%) |
20 (48%) |
|
| 男性 |
6 (19%) |
17 (40%) |
|
| 女 |
25 (81%) |
25 (60%) |
0.08 |
|
| 组织学 |
|
|
0.92 |
| 乳头状甲状腺癌 |
29 (94%) |
41 (98%) |
|
| 经典的变体 |
9 (29%) |
10 (24%) |
|
| 滤泡性变异 |
6 (19%) |
9 (21%) |
|
| 混合古典/卵泡变体 |
4 (13%) |
6 (14%) |
|
| 积极的变异 |
3 (10%) |
5 (12%) |
|
| 囊性变异 |
1 (3%) |
0 (0%) |
|
| 变体不可用 |
6 (19%) |
11 (26%) |
|
| 滤泡性甲状腺癌 |
0 (0%) |
0 (0%) |
|
| 许特耳氏细胞甲状腺癌 |
0 (0%) |
0 (0%) |
|
| 低分化癌 |
1 (3%) |
1 (3%) |
|
| 甲状腺癌未指定 |
1 (3%) |
0 (0%) |
|
|
| 的大小主要甲状腺癌(cm) |
2.9±1.5 |
2.2±1.5 |
0.09 |
| 中位数 |
2.6 |
2.0 |
|
|
|
| (b) |
|
| 参数 |
失业的
() |
rhTSH
() |
价值 |
|
| 肿瘤分期 |
|
|
0.59 |
| 1 |
7 (23%) |
13 (31%) |
|
| 2 |
6 (19%) |
4 (10%) |
|
| 3 |
15 (48%) |
22 (52%) |
|
| 4 |
3 (10%) |
3 (7%) |
|
| 4 b |
0 (0%) |
0 (0%) |
|
|
| 淋巴结分期 |
|
|
0.73 |
| 1 |
21 (68%) |
30 (71%) |
|
| 1 b |
10 (32%) |
12 (29%) |
|
|
| 转移分期 |
|
|
0.24 |
| 0 |
30 (97%) |
42 (100%) |
|
| 1 |
1 (3%) |
0 (0%) |
|
|
| 与分期 |
|
|
0.17 |
| 1 |
22 (71%) |
22 (52%) |
|
| 2 |
1 (3%) |
0 (0%) |
|
| 3 |
5 (16%) |
13 (31%) |
|
| 4 |
3 (10%) |
7 (17%) |
|
| 4 b |
0 (0%) |
0 (0%) |
|
| 4摄氏度 |
0 (0%) |
0 (0%) |
|
|
| ATA复发风险 |
|
|
0.33 |
| 低 |
0 (0%) |
0 (0%) |
|
| 中间 |
23 (74%) |
37 (88%) |
|
| 高 |
8 (26%) |
5 (12%) |
|
|
| 意大利广播电视公司管理活动(GBq) |
4.58±1.49 |
4.52±0.92 |
0.48 |
|
| 随访持续时间(年) |
8.6±2.4 |
6.8±2.1 |
0.01 |
|
|
